Clinical Trials Browser

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms

Rectal Neoplasms

Adenocarcinoma, Carcinoma, Rectal Neoplasms, Colorectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Pathologic Complete Response, Rectal Neoplasms

Rectal Neoplasms

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Neoplasms, Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Adenoviridae Infections, Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Colonic Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Rectal Neoplasms, Colorectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Clinical Trials

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

CHIMERA

A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

WW3

mRCAT-E

Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients

GRECCAR8

Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer

A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer

Colon Neoadjuvant FOLFOXIRI Study

OPERA

JANUS

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

SPARC

Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

mRCAT-III

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial

Néofirinox

A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer

STAR-TREC

Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer

ACO/ARO/AIO-21

NORMANDY

CEDAR

CASINOs

TRACER

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure

TORCH-R

Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

GRECCAR12

Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

TAUTEM-T1

Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer

Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study

Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma